{"id":"NCT00641056","sponsor":"AstraZeneca","briefTitle":"Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION - 3)","officialTitle":"Efficacy of Once-Weekly Exenatide Long-Acting Release and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-04","primaryCompletion":"2009-05","completion":"2009-11","firstPosted":"2008-03-21","resultsPosted":"2012-07-04","lastUpdate":"2015-06-15"},"enrollment":467,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Exenatide Once Weekly","otherNames":[]},{"type":"DRUG","name":"Insulin Glargine","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to compare the effects of 2.0 mg exenatide once weekly and insulin glargine, titrated to glucose targets using the algorithm described by Yki- JÃ¤rvinen et al.(2007), with respect to glycemic improvements, body weight, fasting lipids, safety, and tolerability.","primaryOutcome":{"measure":"Change in HbA1c From Baseline to Week 26","timeFrame":"Baseline, Week 26","effectByArm":[{"arm":"Exenatide Once Weekly","deltaMin":-1.47,"sd":0.05},{"arm":"Insulin Glargine","deltaMin":-1.31,"sd":0.06}],"pValues":[{"comp":"OG000 vs OG001","p":"0.017"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":15},"locations":{"siteCount":75,"countries":["United States","Australia","Belgium","Czechia","Denmark","France","Germany","Greece","Hungary","Mexico","Netherlands","Puerto Rico","Russia","South Korea","Spain","Taiwan"]},"refs":{"pmids":["22357185","32306296","24731672","23748506","23522121","22236356","20609969"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":233},"commonTop":["Nasopharyngitis","Headache","Nausea","Diarrhoea","Injection site nodule"]}}